Regen BioPharma, Inc. (RGBPP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regen BioPharma, Inc. (RGBPP) trades at $0.003. Regen BioPharma, Inc. is a biotechnology company focused on developing regenerative medical applications. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for RGBPP: RGBPP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGBPP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RGBPP: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Regen BioPharma, Inc. (RGBPP) Healthcare & Pipeline Overview
Regen BioPharma, Inc., a development-stage biotech firm, concentrates on regenerative medicine, specifically identifying small molecules targeting NR2F6 for oncology and autoimmune therapies. With a small team and early-stage products, the company operates in a high-risk, high-reward segment of the healthcare sector, seeking to innovate in immune cell modulation.
What Is the Investment Thesis for RGBPP?
Regen BioPharma, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on NR2F6 modulation for both oncology and autoimmune diseases offers potential for significant breakthroughs. However, the company's small size (1 employee) and early stage of development mean that it faces substantial challenges in securing funding, navigating regulatory hurdles, and successfully completing clinical trials. With a negative P/E ratio of -0.04 and a profit margin of -730.0%, the company's financial performance reflects its current development stage. The high beta of 2.76 indicates high volatility. Success hinges on the company's ability to advance its research and development efforts and secure partnerships or funding to support its operations.
Based on FMP financials and quantitative analysis
RGBPP Key Highlights
Regen BioPharma operates with a market capitalization of $0.00B, reflecting its early stage and speculative nature.
- The company's negative P/E ratio of -0.04 indicates that it is not currently profitable, typical for development-stage biotech firms.
- A profit margin of -730.0% highlights significant expenses relative to revenue, emphasizing the need for successful product development and commercialization.
- The company reports a gross margin of 100.0%, which may reflect specific revenue recognition or accounting practices, but should be interpreted with caution given the overall financial context.
- Regen BioPharma's beta of 2.76 suggests high volatility compared to the broader market, indicating a higher degree of risk for investors.
Who Are RGBPP's Competitors?
RGBPP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | +0.00% | $25.7M | 43 |
| IBOGF Universal Ibogaine Inc. | $0.02 | +5.91% | $6.73M | 47 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGBPP's Key Strengths?
Focus on a specific and promising target (NR2F6).
- Potential for dual applications in oncology and autoimmune diseases.
- Innovative approach to immune modulation.
What Are RGBPP's Weaknesses?
Early stage of development with no approved products.
- Limited financial resources and small team.
- High dependence on research and development success.
What Could Drive RGBPP Stock Higher?
Announcement of preclinical study results for lead compounds (Timeline: 6-12 months).
- Filing of patent applications for novel NR2F6 modulators (Timeline: 3-6 months).
- Exploration of potential partnerships with pharmaceutical companies (Timeline: Ongoing).
- Initiation of Phase 1 clinical trials for oncology therapy (Timeline: 2-3 years).
- Pursuit of orphan drug designation for relevant indications (Timeline: Ongoing).
What Are the Key Risks for RGBPP?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure funding for research and development.
- Clinical trial failures and regulatory setbacks.
- Competition from larger and more established biotech companies.
- Intellectual property disputes and patent infringement.
- High volatility and liquidity risks associated with OTC trading.
What Are the Growth Opportunities for RGBPP?
- Expansion into New Therapeutic Areas: Regen BioPharma could explore additional therapeutic applications for its NR2F6 modulation technology. The market for targeted immunotherapies is expanding rapidly, with significant unmet needs in various cancers and autoimmune disorders. By diversifying its pipeline, Regen BioPharma can reduce its reliance on a single indication and increase its potential for success. This expansion could involve preclinical studies and partnerships with research institutions, with a timeline of 3-5 years for initial clinical trials.
- Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions can provide Regen BioPharma with access to funding, expertise, and resources necessary to accelerate its drug development programs. Collaborations can also facilitate clinical trials and regulatory approvals. The market for biotech partnerships is robust, with numerous opportunities for companies with promising technologies. Securing a major partnership within the next 2-3 years could significantly enhance Regen BioPharma's prospects.
- Securing Orphan Drug Designation: Obtaining orphan drug designation for its therapies can provide Regen BioPharma with several benefits, including market exclusivity, tax credits, and reduced regulatory fees. This designation is available for drugs that treat rare diseases or conditions affecting fewer than 200,000 people in the United States. The orphan drug market is attractive due to the reduced competition and potential for premium pricing. Pursuing orphan drug designation for relevant indications within the next year could provide a significant competitive advantage.
- Advancing Clinical Trials: Progressing its lead compounds into clinical trials is crucial for demonstrating the safety and efficacy of Regen BioPharma's therapies. Successful clinical trials can attract investor interest, validate the company's technology, and pave the way for regulatory approvals. The clinical trial process is lengthy and expensive, but it is essential for bringing new drugs to market. Initiating Phase 1 clinical trials within the next 2-3 years is a key milestone for Regen BioPharma.
- Exploring International Markets: Expanding its operations into international markets can provide Regen BioPharma with access to new patient populations and revenue streams. The global market for regenerative medicine is growing rapidly, with significant opportunities in Europe, Asia, and Latin America. Entering these markets may require partnerships with local distributors or establishing a presence through subsidiaries. A phased approach to international expansion over the next 3-5 years could diversify Regen BioPharma's geographic footprint.
What Are RGBPP's Competitive Advantages?
- Proprietary knowledge of NR2F6 modulation.
- Potential for patent protection on identified small molecules.
- Early mover advantage in specific therapeutic areas.
What Does RGBPP Do?
Regen BioPharma, Inc., founded in 2012 and based in La Mesa, California, is a biotechnology company focused on the development of regenerative medical applications. The company's core activity involves identifying small molecules that can either inhibit or express the NR2F6 gene. This modulation is intended to activate immune cells for oncology applications, essentially boosting the body's ability to fight cancer. Conversely, the same approach is used to suppress immune cells for the treatment of autoimmune diseases, where the immune system mistakenly attacks healthy tissues. Currently, Regen BioPharma is in the early stages of developing its products and therapies. This means the company is primarily engaged in research and preclinical studies, with a focus on identifying and validating potential drug candidates. The company's approach is centered around targeted immune modulation, aiming to create therapies that are both effective and have minimal side effects. Given its early stage, Regen BioPharma's success is heavily reliant on its ability to successfully navigate the complex and highly regulated drug development process.
What Products and Services Does RGBPP Offer?
- Identifies small molecules that modulate the NR2F6 gene.
- Develops therapies for oncology applications by activating immune cells.
- Develops therapies for autoimmune diseases by suppressing immune cells.
- Conducts early-stage research and preclinical studies.
- Aims to create targeted immune modulation therapies.
- Focuses on regenerative medical applications.
How Does RGBPP Make Money?
- Focuses on research and development of regenerative medicine applications.
- Seeks to identify and validate potential drug candidates.
- Aims to generate revenue through licensing agreements or eventual commercialization of therapies.
What Industry Does RGBPP Operate In?
Regen BioPharma operates within the highly competitive and rapidly evolving biotechnology industry. This sector is characterized by intense research and development, stringent regulatory requirements, and a constant race to innovate. The regenerative medicine market, which Regen BioPharma targets, is projected to experience substantial growth, driven by an aging population and increasing demand for advanced therapies. Competition includes both large pharmaceutical companies and smaller biotech firms, each vying for market share. Regen BioPharma's success depends on its ability to differentiate itself through novel technologies and strategic partnerships.
Who Are RGBPP's Key Customers?
- Potentially patients suffering from cancer.
- Potentially patients suffering from autoimmune diseases.
- Future pharmaceutical companies through licensing agreements.
Financial Health
Regen BioPharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Regen BioPharma, Inc. stands at 11.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Regen BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Mesa, US. The company is led by CEO David Raymond Koos. RGBPP has traded publicly since 2016.
RGBPP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on a specific and promising target (NR2F6).
- Potential for dual applications in oncology and autoimmune diseases.
- Innovative approach to immune modulation.
- Upcoming: Announcement of preclinical study results for lead compounds (Timeline: 6-12 months).
Bear Case
- Early stage of development with no approved products.
- Limited financial resources and small team.
- High dependence on research and development success.
- Potential: Failure to secure funding for research and development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RGBPP Latest News
No recent news available for RGBPP.
RGBPP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGBPP.
Price Targets
Wall Street price target analysis for RGBPP.
RGBPP MoonshotScore
What does this score mean?
The MoonshotScore rates RGBPP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Raymond Koos
CEO
David Raymond Koos serves as the CEO of Regen BioPharma, Inc. His background includes experience in managing early-stage companies and navigating the complexities of the biotechnology industry. He has been involved in various aspects of corporate development, including fundraising, strategic planning, and business development. His leadership is crucial for guiding the company through its research and development efforts.
Track Record: Under David Raymond Koos's leadership, Regen BioPharma has focused on identifying and developing small molecules for immune cell modulation. Key milestones include advancing preclinical studies and exploring partnerships to support the company's growth. His strategic decisions have shaped the company's direction and focus on regenerative medicine applications.
RGBPP OTC Market Information
The OTC Other tier, where Regen BioPharma trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, as there is less regulatory oversight and transparency. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher potential for price manipulation.
- Increased risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review any legal or regulatory issues involving the company.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Focus on regenerative medicine applications.
- Development of therapies for oncology and autoimmune diseases.
- CEO with experience in managing early-stage companies.
What Investors Ask About Regen BioPharma, Inc. (RGBPP) — Healthcare
What does Regen BioPharma, Inc. do?
Regen BioPharma, Inc. is a biotechnology company focused on developing regenerative medical applications. The company identifies small molecules that modulate the NR2F6 gene to activate immune cells for oncology applications and suppress immune cells for autoimmune diseases. Regen BioPharma is in the early stages of developing its products and therapies, aiming to create targeted immune modulation therapies.
What do analysts say about RGBPP stock?
As of 2026-03-18, there is no available analyst coverage for Regen BioPharma, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as revenue projections and earnings estimates are not available.
What are the main risks for RGBPP?
Regen BioPharma, Inc. faces several significant risks typical of early-stage biotechnology companies. These include the risk of failure to secure funding for research and development, potential clinical trial failures and regulatory setbacks, competition from larger and more established biotech companies, intellectual property disputes, and the high volatility and liquidity risks associated with OTC trading. Investors should carefully consider these risks before investing in Regen BioPharma, Inc.
What are the key factors to evaluate for RGBPP?
Evaluate RGBPP on fundamentals, analyst consensus, and risk factors. Regen BioPharma, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. Not financial advice.
How frequently does RGBPP data refresh on this page?
RGBPP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGBPP's recent stock price performance?
Regen BioPharma, Inc. (RGBPP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific and promising target (NR2F6). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGBPP overvalued or undervalued right now?
Regen BioPharma, Inc. (RGBPP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGBPP before investing?
Before investing in Regen BioPharma, Inc. (RGBPP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is in the early stages of development, and its future prospects are highly uncertain.
- Investment in OTC stocks carries a high degree of risk.